As part of a ‘world-leading arrangement,’ the NHS will fund a cholesterol wonder medication that will save thousands of lives.


As part of a ‘world-leading arrangement,’ the NHS will fund a cholesterol wonder medication that will save thousands of lives.

The National Health Service (NHS) has purchased a CHOLESTEROL wonderdrug in a “world-leading deal” that could save thousands of lives in the future.

Inclisiran, a groundbreaking new medication, is administered twice a year as an injectable and can be used in conjunction with statins. It comes after the NHS reached a historic agreement with Novartis, a Swiss pharmaceutical company, to provide lifesaving treatment to 300,000 patients over the next three years. In the future, that number might reach over half a million.

Within the next decade, Inclisiran is expected to prevent 55,000 heart attacks and strokes, saving 30,000 lives.

“The NHS is dedicated to employing cutting-edge treatments to preserve and improve patients’ lives,” NHS Chief Executive Amanda Pritchard said.

“Heart disease is still one of the leading causes of death, so it’s excellent that patients with dangerously high cholesterol levels now have such an efficient and easy treatment.

“While being fair to taxpayers, this world-leading contract for the deployment of Inclisiran will save lives and enable hundreds of thousands of individuals to benefit from this groundbreaking treatment.”

In England, more than two out of every five people have excessive cholesterol, putting them at a high risk of heart disease.

Heart disease is the world’s leading cause of death, accounting for around a quarter of all fatalities in England each year.

However, under the new agreement, nurses will soon be able to inject Inclisiran at GP surgeries across England, allowing patients to avoid frequent hospital appointments.

The medicine will be given again after three months and then twice a year after the original dose.

It comes after clinical trials revealed that the medication was effective in lowering the level of LDL-C, a type of fatty molecule found in the blood.

People with high LDL-C levels are more likely to have a heart attack or stroke.

The cholesterol-lowering medication boosts the liver’s ability to eliminate bad cholesterol from the circulation by using RNA interference (RNAi).

The NHS’s Long Term Plan, which also details how the health service will take a new population health strategy over the next decade, states that preventing thousands of heart attacks and strokes over the next ten years is a top objective.

“This ground-breaking breakthrough medication further demonstrates,” Health Secretary Sajid Javid said in a statement.


Comments are closed.